These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1272 related articles for article (PubMed ID: 31835068)

  • 1. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
    Boudreau DM; Lapham G; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Campbell CI; Rossom RC; Binswanger IA; Yarborough BJ; Arnsten JH; Cunningham CO; Glass JE; Murphy MT; Zare M; Hechter RC; Ahmedani B; Braciszewski JM; Horigian VE; Szapocznik J; Samet JH; Saxon AJ; Schwartz RP; Bradley KA
    J Subst Abuse Treat; 2020 Mar; 112S():41-48. PubMed ID: 32220410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.
    Bagley SM; Chavez L; Braciszewski JM; Akolsile M; Boudreau DM; Lapham G; Campbell CI; Bart G; Yarborough BJH; Samet JH; Saxon AJ; Rossom RC; Binswanger IA; Murphy MT; Glass JE; Bradley KA;
    Addict Sci Clin Pract; 2021 Jul; 16(1):46. PubMed ID: 34233750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
    Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
    J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
    Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
    JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
    Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
    Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study.
    Raman SR; Ford CB; Hammill BG; Clark AG; Clifton DC; Jackson GL
    Addict Sci Clin Pract; 2023 Jul; 18(1):42. PubMed ID: 37434260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity.
    Ross RK; Inose S; Shulman M; Nunes EV; Zalla LC; Burlew AK; Rudolph KE
    JAMA Netw Open; 2024 Oct; 7(10):e2436612. PubMed ID: 39365581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
    Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
    Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.
    Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI
    Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
    Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
    N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.